肝素酶在肿瘤侵袭转移中的作用及其机制

摘要/Abstract

摘要： 肝素酶(HPSE)是一种糖苷内切酶,能特异性水解位于细胞表面、细胞外基质及基底膜的硫酸乙酰肝素。肝素酶可促进肿瘤浸润、转移和血管生成,并参与免疫监视、胚胎植入等病理生理

Abstract: Heparanase(HPSE) is heparan sulfate-degrading enzymes, which could specifically degrade the heparan sulfate proteoglycans associated with the cell surface, extracellular matrix and basement membrane. It can promote tumor invasion, metastasis and angiogenesis, moreover participate in the process of pathophysiological as immunological surveillance and embryo impantation. This review will summerize the role of HPSE in facilitating tumor metastatic and the advance in its inhibitor.

Key words: heparanase, tumor metastasis, angiogenesis

中图分类号:

聂宸麟, 陈晓鹏. 肝素酶在肿瘤侵袭转移中的作用及其机制[J]. 中国临床药理学与治疗学, 2014, 19(7): 812-817.

NIE Chen-lin, CHEN Xiao-peng. Role of heparanase in the invasion and metastasis of tumor and its mechanism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 812-817.

参考文献

[1] Vlodavsky I, Friedmann Y, Elkin M, et al.Mammalianheparanase: genecloning expression and function in tumor progression and metastasis[J]. Nat Med, 1999, 5(7): 793-802.
[2] Sanderson RD, Yang Y.Syndecan-1: a dynamic regulator of the myeloma microenvironment[J]. Clin Exp Metastasis, 2008, 25(2): 149-159.
[3] Komori H, Beppu T, Baba H, et al.Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma[J]. Nihon Rinsho, 2010, 68(7): 833-836.
[4] Liu H, Li P, Zhai Y, et al.Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma[J]. World J Gastroenterol, 2010, 16(35): 4410-4415.
[5] Shirakawa H, Suzuki H, Shimomura M, et al.Glypican-3 expression is correlated with poor prognosisin hepatocellular carcinoma[J]. Cancer Sci, 2009, 100(8): 1403-1407.
[6] 阮健, 郑大勇, 罗荣城. 磷脂酰肌醇蛋白聚糖3在恶性肿瘤中的表达及其临床应用[J].肿瘤, 2011, 31(9): 863-866.
[7] Wu WJ, Pan CE, Liu QG, et al.Expression of heparanase and nuclear factor kappa B in pancreatic adenocarcinoma[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2007, 27(8): 1267-1270.
[8] Han J, Woytowich AE, Mandal AK, et al.Heparanase upregulation in high glucose-treated endothelial cells is prevented by insulin and heparin[J]. Exp Biol Med (Maywood), 2007, 232(7): 927-934.
[9] 王静, 杨洋, 罗荣城. Syndecan-1-肿瘤微环境的重要调节者[J]. 肿瘤防治研究, 2010, 37(1): 117-119.
[10] Iozzo RV, Sanderson RD.Proteoglycans in cancer biology, tumour microenvironment and angiogenesis[J ]. Cell Mol Med, 2011, 15(5): 1013-1031.
[11] Nadir Y, Brenner B, Gingis-Velitski S, et al.Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells[J]. Thromb Haemost, 2008, 99(1): 133-141.
[12] Nadir Y, Brenner B.Heparanase procoagulant effects and inhibition by heparins[J]. Thromb Res, 2010, 125(2): S72-76.
[13] Wang GB, Zhou XY, Wang XQ.Relationship between serum heparanase and microscopic venous invasion in patients with hepatocellular carcinoma[J]. Am J Clin Pathol, 2010, 134(2): 242-248.
[14] Kessenbrock K, Plaks V, Werb Z.Matrix metalloproteinases:regulators of the tumor microenvironment[J]. Cell, 2010, 141(1): 52-67.
[15] Mason SD, Joyce JA.Proteolytic networks in cancer[J]. Trends Cell Biol, 2011, 21(4): 228-237.
[16] Gocheva V, Joyce JA.Cysteine cathepsins and the cutting edge of cancer invasion[J]. Cell Cycle, 2007, 6(1): 60-64.
[17] Lankelma JM, Voorend DM, Barwari T, et al.Cathepsin L,target in cancer treatment[J]? Life Sci, 2010, 86(7/8): 225-233.
[18] Turk B, Turk D, Turk V.Lysosomal cysteine proteases: more than scavengers[J]. Biochim Biophys Acta, 2000, 1477(1/2): 98-111.
[19] Stupack DG, Cheresh DA.Integrins and angiogenesis[J]. Curr Top Dev Biol, 2004, 64: 207-238.
[20] Noël A, Jost M, Maquoi E.Matrix metalloproteinases at cancer tumor-host interface[J]. Semin Cell Dev Biol, 2008, 19(1): 52-60.
[21] Van Damme J, Struyf S, Opdenakker G.Chemokineprotease interactions in cancer[J]. Semin Cancer Biol, 2004, 14(3): 201-208.
[22] 杨仕明, 汤旭东, 陈婷, 等. 肝素酶:一种新的广谱的肿瘤转移相关抗原在中晚期肿瘤免疫治疗中作用的研究进展[J] . 世界华人消化杂志, 2007, 15(8): 849.
[23] 王宁,孙治君. 乙酰肝素酶对乳腺癌等恶性肿瘤的影响[J]. 现代肿瘤医学, 2012,20(3): 460-462.
[24] Hoffmann Ac, Mori R, Vallbohmer D, et al.Hish espression of heparanase is significantly associated with dedifferentiation and lymphnode metastasis in patients with pancreatic ductal adenocarcinomasand carrelated to PDGFA and via H1F1a to HB-EGF and bFGF[J]. J Gastrointest Surg, 2008, 12(10): 1674.
[25] Cohen E, Doweck I, Naroditsky I, et al.Heparanase is overxepressed in lung cancer and correlates inversely with patient survival[J]. Cancer, 2008, 113(5): 1004.
[26] Inamine M, Naqai Y, Hirakawa M, et al.Heparanase expression in endometrial cancer:analysis of immunohistochemistry[J]. J obstet Gynaecol, 2008, 28(6): 634.
[27] Thompson CA, Purushothaman A, Ramani VC, et al.Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes[J]. J Biol Chem, 2013, 288(14): 10093-10099.
[28] Yang Y, Macleod V, Miao HQ, et al.Heparanase enhances syndecan-1 shedding: A novel mechanism for stimulation of tumor growth and metastasis[J]. J Biol Chem, 2007, 282(18): 13326-13333.
[29] Ramani VC, Pruett PS, Thompson CA, et al.Heparan sulfate chains of syndecan-1 regulate ectodomain shedding[J]. J Biol Chem, 2012, 287(13): 9952-9961.
[30] Baietti MF, Zhang Z, Mortier E, et al.Syndecan-syntenin-ALIX regulates thebiogenesis of exosomes[J]. Nat Cell Biol, 2012, 14(7): 677-685.
[31] Zcharia E, Jia J, Zhang X.Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases[J]. PLoS One, 2009,4(4): e5181.
[32] Purushothaman A, Chen L, Yang Y, et al.Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma[J]. J Biol Chem, 2008, 283(47): 32628-32636.
[33] Vlodavsky I, Beckhove P, Lerner I, et al.Significance of Heparanase in Cancer and Inflammation[J]. Cancer Microenviron, 2012, 5(2): 115-132.
[34] Wu W, Pan C, Meng K, et al.Hypoxia activates heparanase expression in an NF-kappaB dependent manner[J]. Oncol Rep, 2010, 23(1): 255-261.
[35] Yu SJ, Kang XH, Zhang JN, et al.Effects of small interfering RNA targeting heparanase-1 combined with heparin on invasiveness of mouse hepatocellular carcinoma cell lines[J]. Chin J Cancer, 2010, 29(9): 816-823.
[36] Zhang L, Sullivan PS, Goodman JC, et al.MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase[J]. Cancer Res, 2011, 71(3): 645-654.
[37] Zheng LD, Jiang GS, Pu JR, et al.Stable knockdown of heparanase expression in gastric cancer cells in vitro[J]. World J Gastroenterol, 2009, 15(43): 5442-5448.
[38] Dredge K, Hammond E, Handley P, et al.PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models[J]. Br J Cancer, 2011, 104(4):635-642.
[39] Ritchie JP, Ramani VC, Ren Y, et al.SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis[J]. Clin Cancer Res, 2011,17(6):1382-1393.
[40] Dredge K, Hammond E, Handley P, et al.PG545, a dual heparanase and angiogenesis inhibitor, induces potent antitumour and anti-metastatic efficacy in preclinical models[J]. Br J Cancer, 2011, 104(4): 635-642.
[41] Hammond E, Brandt R, Dredge K.PG545, a heparansulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model[J]. PLoS One, 2012, 7(12): e52175.
[42] Ostapoff KT, Awasthi N, Cenik BK, et al.PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer[J]. Mol Cancer Ther, 2013,12(7):1190-1201.
[43] Basche M, Gustafson DL, Holden SN, et al.A phase I bio-logical and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors[J]. Clin Cancer Res, 2006, 12(18): 5471.
[44] Lewis KD, Robinson WA, Millward MJ, et al.A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma[J]. Invest New Drugs, 2008, 26(1):89-94.
[45] Cassinelli G, Lanzi C, Tortoreto M, et al.Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models[J]. Biochem Pharmacol, 2013, 85(10):1424-1432.
[46] 宫亮, 杨和平.循环中血小板活化对肿瘤血行转移的影响[J]. 山东医药,2011, 51(4):103-105.
[47] Tsuruo T, Fujita N.Platelet aggregation in the formation of tumor metastasis[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2008, 84(6):189-198.